Tuesday 13 October 2026
Export ENTX’s income statement to Excel — free account
Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.51
0.14
−5.28%
Follow ENTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.57 | 6.76 | 7.57 | 8.76 | |
Current Ratio |
10.83 | 6.94 | 7.93 | 8.98 | |
Net Debt/EBITDA |
5.11 | 4.90 | 3.38 | 4.05 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.61 | 0.88 | 0.47 | |
Capex/Depreciation |
(5.37) | (3.86) | 0.00 | (0.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.04) | (0.06) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | (0.06) | (0.07) | |
Cash per Share |
0.35 | 0.32 | 0.25 | 0.37 | |
Shareholders Equity per Share |
0.32 | 0.28 | 0.22 | 0.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.32 | 0.28 | 0.22 | 0.14 | |
Free Cash Flow |
(2.54) | (1.86) | (3.09) | (3.47) | |
Working Capital |
15.44 | 13.10 | 10.92 | 16.79 | |
Capital Expenditures |
(0.04) | (0.03) | — | 0.00 | |
Net Current Asset Value |
14.83 | 12.41 | 10.05 | 6.68 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.20 | 0.29 | 0.20 | 0.48 | |
Average Assets |
12.57 | 12.69 | 17.36 | 19.57 | |
Average Common Equity |
10.84 | 10.59 | 15.03 | 12.26 |
Columns are period end dates